MedTrace Logo

A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

NCT00808028 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 538

Last updated 2015-04-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and immunogenicity of an investigational meningococcal B rLP2086 vaccine in adolescents aged 11 to 18 years old.

Conditions

  • Meningitis, Meningococcal

Interventions

BIOLOGICAL

meningococcal B rLP2086 vaccine.

vaccine, 0.5 mL, 0 - 2 - 6 to 9 months

BIOLOGICAL

meningococcal B rLP2086 vaccine.

vaccine, 0.5 mL, 0 - 2 - 6 to 9 months

BIOLOGICAL

meningococcal B rLP2086 vaccine.

vaccine, 0.5 mL, 0 - 2 - 6 to 9 months

OTHER

normal saline (placebo)

vaccine, 0.5 mL, 0 - 2 - 6 to 9 months

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
11 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • Australia
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00808028 on ClinicalTrials.gov